Scancell (LON:SCLP) Trading 4.1% Higher – Here’s Why

Shares of Scancell Holdings plc (LON:SCLP) shot up 4.1% during mid-day trading on Friday . The company traded as high as GBX 14 and last traded at GBX 13.01. 1,196,952 shares traded hands during mid-day trading, a decline of 43% from the average session volume of 2,108,023 shares. The stock had previously closed at GBX 12.50.

Scancell Price Performance

The company’s 50 day simple moving average is GBX 11.45 and its 200-day simple moving average is GBX 10.42. The company has a market capitalization of £135.05 million, a price-to-earnings ratio of -23.66 and a beta of 0.35. The company has a current ratio of 3.42, a quick ratio of 13.01 and a debt-to-equity ratio of -566.79.

Scancell (LON:SCLP) last released its earnings results on Thursday, January 29th. The company reported GBX (0.55) EPS for the quarter. On average, equities research analysts predict that Scancell Holdings plc will post -2.5361112 earnings per share for the current fiscal year.

About Scancell

Scancell (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma.